Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Many insurance companies do not cover Mounjaro for weight loss because it is only approved as a diabetes medication
Lillys small-molecule GLP-1 agonist orforglipron (brand Foundayo) also gained FDA approval in April 2026 for weight loss and is expected to launch in 2027, marking a breakthrough as the first non-peptidic GLP-1 pill ( [35] )
Your GP can: Assess your current weight, BMI, and metabolic health to determine clinical need Review existing treatment options that are currently licensed and available in the UK, which may include orlistat, naltrexone/bupropion (Mysimba), semaglutide 2.4 mg (Wegovy approved by the MHRA for weight management and subject to NICE guidance on eligibility, service setting, and treatment duration), and tirzepatide (Mounjaro check current MHRA and NICE status at the time of reading, as licensing and commissioning arrangements may have been updated) Discuss eligibility for NHS Tier 3 or Tier 4 specialist weight management services , in line with NICE guidance on obesity management, where pharmacotherapy is used as an adjunct to structured lifestyle intervention Signpost you to relevant clinical trials via the Be Part of Research portal or ClinicalTrials.gov if you wish to explore participation in retatrutide research It is important to approach information about investigational medicines with appropriate caution
The body composition data certainly suggests this possibility
doi: 10.1016/j.clp.2017.10.007 29 ShiYAvatapalleHBSkaeMSPadidelaRNewbouldMRigbyLet al
US$ 22.18
US$ 25.57
US$ 20.56
US$ 26.64
US$ 23.27
US$ 20.17
